Skip to content

Detection and/or Evaluation of Dense Breast Abnormalities Using Tomosynthesis and Digital Mammography

Assessment of Emerging Technology: Comparison of Breast Tomosynthesis and Digital Mammography in the Evaluation of Heterogeneously Dense and Extremely Dense Breasts

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00722059
Enrollment
50
Registered
2008-07-25
Start date
2006-04-30
Completion date
2013-10-31
Last updated
2014-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Abnormalities, Breast Neoplasms

Brief summary

The purpose of this study is to compare 3D mammography with digital mammography in women with dense breasts for the detection and evaluation of masses and/or breast cancer.

Interventions

3D breast imaging

Sponsors

University of Michigan
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
30 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Females 30 years of age or older. * Dense Breasts. * Has undergone clinical two view mammogram and diagnostic breast imaging evaluation. * Suspicious or palpable mass and scheduled for biopsy.

Exclusion criteria

* Pregnant or lactating women. * Prior personal history of breast cancer. * Prior breast augmentation with implants or silicon injection. male patients. * No two view mammogram as part of breast imaging evaluation. * Breast density of almost entirely fatty/scattered fibroglandular densities.

Design outcomes

Primary

MeasureTime frameDescription
Measure of digital tomosynthesis and digital mammography test performance.3 weeksInterest of sensitivity, specificity and area under region of concern curve for malignant mass detection. During review, the number of masses and location and size of each mass will be recorded. An additional estimate of probability of malignancy will be recorded for each image sets.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026